Plain-English translation of NCT07012395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing new long-acting antibody medications (, , and ) designed to treat ulcerative colitis that is not controlled with current treatments. The study will first test each medication individually to ensure it is safe, and then move to a second phase where different medications are tested alone and in combinations against a placebo to see which approach works best.
Ulcerative colitis can be severely disabling, and many patients don't respond well enough to existing treatments. This trial is exploring whether new antibody-based therapies might offer better control of the disease, either when used alone or when combined together.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In the first phase, you would receive one of the new medications openly (everyone knows what they are getting) to check for safety. In the second phase, you would be randomly assigned to receive either one of the medications, a combination of medications, or a placebo—and neither you nor the study team would initially know which one you received. You would have regular visits for blood tests, endoscopy, and symptom checks to see how well the treatment is working.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States